Sunday, June 11, 2017 8:22:43 AM
The main difference between the two is that Indoximod is mainly a IDO2 inhibitor, Epadostat a IDO1 inhibitor (like BMS's). Melanoma shows both IDO1 and IDO2 overexpression, whereas Pancreatic Cancer and AML have a significant IDO2 overexpression. IDO2 overxpression is high in some tumor types, for which Indoximod will have no or little competition: two of them are Pancreatic Cancer and AML, but
also gastric and colon cancers
http://www.sciencedirect.com/science/article/pii/S2452336417300201
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3176891/
http://www.bloodjournal.org/content/126/23/1191?sso-checked=true
FEATURED Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • Apr 22, 2024 8:49 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM